What is interstitial lung disease, including its causes, diagnostic approach, and treatment options?

Understanding Interstitial Lung Disease

Interstitial lung disease (ILD) encompasses a diverse group of over 300 disorders characterized by inflammation and/or fibrosis of the lung parenchyma, leading to impaired gas exchange, progressive dyspnea, and potentially end-stage respiratory failure. 1, 2

What is ILD?

ILD affects the interstitium (the tissue and space around the air sacs), though it can also involve the alveolar space and bronchial system. The disease typically presents with:

• Dyspnea on exertion (primary symptom)
• Dry cough (approximately 30% of patients)
• Bibasilar inspiratory crackles ("Velcro-like" quality on examination) 3, 2

In the US, ILD affects approximately 650,000 people and causes 25,000-30,000 deaths annually, with prevalence estimates in Europe ranging from 72.1 to 164.2 cases per 100,000 1, 2.

Major Categories and Causes

Idiopathic Interstitial Pneumonias (IIPs)

The most important category includes:

• Idiopathic Pulmonary Fibrosis (IPF): Accounts for approximately 33-55% of all ILD cases, associated with usual interstitial pneumonia (UIP) pattern, and carries the worst prognosis with 5-year survival worse than several cancers 4, 2
• Nonspecific Interstitial Pneumonia (NSIP): 25% of IIPs, generally better prognosis than IPF 4
• Acute Interstitial Pneumonia (AIP): Rare (<2%), fulminant presentation with >60% mortality 3
• Cryptogenic Organizing Pneumonia (COP): 5% of cases 4

Connective Tissue Disease-Associated ILD (CTD-ILD)

Accounts for approximately 20-25% of all ILDs 1, 2:

• Systemic sclerosis-ILD (SSc-ILD): 31% of CTD-ILDs
• Rheumatoid arthritis-ILD (RA-ILD): 39% of CTD-ILDs
• Idiopathic inflammatory myopathy-ILD: Including dermatomyositis, polymyositis, antisynthetase syndrome
• Sjögren's syndrome, systemic lupus erythematosus, mixed connective tissue disease 1

Known Causes

• Hypersensitivity pneumonitis: 15% of ILD cases 2
• Drug-induced ILD: From chemotherapy agents, amiodarone, methotrexate, nitrofurantoin
• Environmental/occupational exposures: Asbestos, silica, organic dusts
• Granulomatous diseases: Sarcoidosis 4, 3

Genetic Factors

• MUC5B gene polymorphisms
• Surfactant protein mutations (particularly in children)
• Telomerase gene mutations 1

Diagnostic Approach

Initial Clinical Assessment

Look specifically for:

• Age >50 years (risk factor for IPF) 3
• Smoking history (increases risk, may coexist with COPD)
• Occupational/environmental exposures (birds, mold, chemicals)
• Medication history (chemotherapy, amiodarone, methotrexate)
• Autoimmune symptoms: Joint pain, skin changes, Raynaud's phenomenon, muscle weakness 1, 3
• Duration >3 months with insidious onset 3

Critical pitfall: Early ILD may be asymptomatic with irreversible lung function loss occurring silently, particularly in CTD patients. Symptoms like fatigue, cough, or dyspnea may be masked by other organ involvement 1.

Pulmonary Function Testing

Essential findings include 3:

• Reduced FVC (forced vital capacity) - restrictive pattern
• Increased FEV1/FVC ratio (>0.7-0.8)
• Decreased DLCO (diffusion capacity for carbon monoxide)
• Increased A-a gradient at rest or with exercise

Prognostic marker: A 5% decline in FVC over 12 months is associated with approximately 2-fold increase in mortality 2.

High-Resolution Computed Tomography (HRCT)

HRCT is the cornerstone of ILD diagnosis with 91% sensitivity and 71% specificity 4, 2.

Key patterns to identify:

• UIP pattern (diagnostic for IPF in correct clinical context):

  • Bibasilar, subpleural reticular opacities
  • Honeycombing
  • Traction bronchiectasis
  • Minimal ground-glass opacities 3

• NSIP pattern: Ground-glass opacities, may have fibrosis but less honeycombing 3

• Organizing pneumonia pattern: Patchy consolidation, peribronchovascular distribution

For CTD-ILD screening: A risk-based approach is recommended using HRCT when patients have risk factors (specific autoantibodies like anti-Scl-70, anti-synthetase antibodies, diffuse cutaneous systemic sclerosis) even without symptoms 1.

Critical pitfall: HRCT misdiagnosis occurs, particularly by less experienced radiologists. Multidisciplinary discussion is essential 4.

Surgical Lung Biopsy

Indications for biopsy 3:

• Clinical, physiological, or radiological features atypical for IPF
• HRCT shows "possible UIP" or indeterminate pattern
• Need to identify specific treatable histopathologic patterns
• To inform prognosis when genetic testing inconclusive
• No contraindications to surgery

Approach: Video-assisted thoracoscopic surgery (VATS) or open thoracotomy from multiple lobes 3.

When biopsy can be avoided: Definite UIP pattern on HRCT in patient >50 years with appropriate clinical context and exclusion of other causes negates need for biopsy 4, 3.

Additional Diagnostic Testing

• Bronchoalveolar lavage (BAL): Primarily to exclude alternative diagnoses (infection, malignancy, eosinophilic pneumonia), not diagnostic for IPF 4, 3
• Autoimmune serologies: ANA, RF, anti-CCP, myositis panel, anti-Scl-70, anti-centromere for CTD screening 1
• Genetic testing: Strongly recommended for infants with ILD and respiratory failure; consider in adults with family history 5
• Disease-specific biomarkers: KL-6, SP-D (not routinely available in all centers) 1

Multidisciplinary Discussion

Essential for accurate diagnosis: Integration of clinical, radiological, and pathological data by pulmonologists, radiologists, and pathologists is mandatory to optimize diagnostic accuracy 1, 4.

Treatment Approaches

For Idiopathic Pulmonary Fibrosis

Antifibrotic therapy is first-line treatment 2:

• Nintedanib or Pirfenidone: Slow annual FVC decline by 44-57%
• Start at first identification of clinical or physiological impairment or documented decline 3, 2

Important caveat: No treatment has been definitively shown to improve survival or quality of life in older guidelines, but newer evidence supports antifibrotic use 3, 2.

For CTD-Associated ILD

Immunomodulatory therapy is the main strategy 2, 6, 7:

• Mycophenolate mofetil: First-line for most CTD-ILD, may slow decline or improve FVC at 12 months
• Rituximab: For systemic sclerosis-ILD and myositis-ILD
• Tocilizumab: For systemic sclerosis-ILD
• Cyclophosphamide: For severe, rapidly progressive disease

For progressive fibrosing CTD-ILD: Consider adding antifibrotic therapy (nintedanib) to immunosuppression 2, 6.

For Progressive Pulmonary Fibrosis (Any Cause)

Antifibrotic therapy with nintedanib or pirfenidone reduces FVC decline regardless of underlying ILD subtype when progressive fibrosing phenotype is present 2.

Corticosteroids

• Not recommended as monotherapy for IPF (may be harmful)
• Used in CTD-ILD: Typically combined with steroid-sparing immunosuppressants
• For acute exacerbations: High-dose methylprednisolone may be used 7, 8

Non-Pharmacological Interventions

Structured exercise/pulmonary rehabilitation 2:

• Reduces symptoms
• Improves 6-minute walk test distance
• Enhances quality of life

Supplemental oxygen 2:

• For patients who desaturate below 88% on 6-minute walk test
• Reduces symptoms and improves quality of life

Lung Transplantation

Refer for evaluation when 3:

• Progressive deterioration despite optimal medical therapy
• Meeting established transplant criteria
• Specific chILD disorders with predictably poor outcomes 5

Outcomes: Median survival of 5.2-6.7 years post-transplant versus <2 years for advanced ILD without transplant 2.

Treatment of Pulmonary Hypertension

Up to 85% of patients with end-stage fibrotic ILD develop pulmonary hypertension. Inhaled treprostinil improves walking distance and respiratory symptoms in this population 2.

Monitoring and Follow-Up

For CTD-ILD Screening and Monitoring 1

Risk-based screening approach:

• Clinical examination at each rheumatology visit
• Annual PFTs (FVC, DLCO) for high-risk patients
• HRCT when risk factors present or PFTs decline
• Disease-specific biomarkers where available

Progressive disease criteria 1:

• Relative decline in FVC ≥10% over 12 months
• Relative decline in DLCO ≥15% over 12 months
• Worsening symptoms plus decline in FVC 5-10%
• Radiographic progression on HRCT

General Monitoring Parameters 3

Assess using combination of:

• Serial PFTs (FVC, DLCO) every 3-6 months
• 6-minute walk test with oxygen saturation
• Symptom assessment
• Serial HRCT (timing based on disease severity and progression risk)

Key Clinical Pitfalls

1. Underdiagnosis of CTD-ILD: Asymptomatic early disease with irreversible loss requires high index of suspicion and proactive screening 1

2. HRCT interpretation errors: Less experienced radiologists may misdiagnose patterns; always use multidisciplinary discussion 4

3. Delayed genetic testing: Particularly critical in infants and those with family history 5

4. Inappropriate use of corticosteroids alone: May harm IPF patients; requires accurate diagnosis first 3

5. Missing progressive fibrosing phenotype: Can occur across multiple ILD subtypes and requires antifibrotic consideration 2

6. Late transplant referral: Should occur before patients become too ill to be candidates 3